Italia markets close in 7 hours 9 minutes

FTSE MIB
34.543,77
-115,78(-0,33%)
Dow Jones
38.852,86
-216,74(-0,55%)
Nasdaq
17.019,88
+99,08(+0,59%)
Nikkei 225
38.556,87
-298,50(-0,77%)
Petrolio
80,46
+0,63(+0,79%)
Bitcoin EUR
62.446,87
-161,61(-0,26%)

NVCR Jun 2024 20.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,7700

0,0000

(0,00%)

In data: 01:46PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in